

# ForPatients

by Roche

Neoplasms Respiratory Tract Neoplasms Non-Small Cell Lung Cancer (NSCLC) Lung Neoplasm Neuroendocrine Carcinoma Solid Tumors Medullary Thyroid Cancer Thoracic Neoplasms Thyroid Cancer Head and Neck Neoplasms

## Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

**Trial Status**  
Completed

**Trial Runs In**  
13 Countries

**Trial Identifier**  
NCT03037385  
2016-004390-41,BLU-667-1101  
BO42863

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in participants with medullary thyroid cancer (MTC), RET-altered NSCLC and other RET-altered solid tumors.

**Hoffmann-La Roche**  
Sponsor

**Phase 1/Phase 2**  
Phase

**NCT03037385 2016-004390-41,BLU-667-1101 BO42863**  
Trial Identifiers

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No